3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
6
Lung Neoplasms
6
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
Gemcitabine
23
Capecitabine
17
Cisplatin
11
Oxaliplatin
10
Fluorouracil
9
Leucovorin
8
Irinotecan
7
Erlotinib Hydrochloride
6
pembrolizumab
5
Radiotherapy
5
Sorafenib
4
Interleukin-12 Subunit p35
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
regorafenib
2
dehydroftorafur
2
Watchful Waiting
2
Trastuzumab
2
Pancreaticoduodenectomy
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Long-Term Synaptic Depression
2
Lapatinib
2
Filgrastim
2
Epirubicin
2
Drug Therapy
2
Dihematoporphyrin Ether
2
Chemotherapy, Adjuvant
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bile Duct Neoplasms
×
Immunotherapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled